Key clinical recommendations include: SGLT2 inhibitors are recommended as first-line therapy in patients with T2DM and established cardiovascular disease (CVD) to reduce the risk of major adverse cardiovascular events (MACE) [2]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.